Glaukos (NYSE:GKOS) COO Sells $2,809,508.42 in Stock

Glaukos Corporation (NYSE:GKOS) COO Joseph Gilliam sold 19,573 shares of Glaukos stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $143.54, for a total value of $2,809,508.42. Following the transaction, the chief operating officer owned 73,419 shares in the company, valued at $10,538,563.26. This trade represents a 21.05% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Glaukos Stock Down 3.0%

NYSE GKOS traded down $4.24 during trading hours on Monday, reaching $135.98. 942,743 shares of the company’s stock were exchanged, compared to its average volume of 790,624. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.73 and a current ratio of 5.43. The company has a market capitalization of $7.96 billion, a price-to-earnings ratio of -41.46 and a beta of 0.94. The company’s 50-day moving average is $114.02 and its two-hundred day moving average is $108.01. Glaukos Corporation has a one year low of $73.16 and a one year high of $146.75.

Glaukos (NYSE:GKOS) last announced its quarterly earnings results on Wednesday, April 29th. The medical instruments supplier reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.12. The firm had revenue of $150.57 million for the quarter, compared to analyst estimates of $137.00 million. Glaukos had a negative net margin of 34.34% and a negative return on equity of 6.92%. The business’s revenue was up 41.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.22) earnings per share. On average, analysts forecast that Glaukos Corporation will post -0.6 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on GKOS. Wall Street Zen upgraded shares of Glaukos from a “hold” rating to a “buy” rating in a report on Saturday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Glaukos in a report on Tuesday, April 21st. William Blair upgraded shares of Glaukos to a “strong-buy” rating in a report on Friday, January 30th. Needham & Company LLC upped their price target on shares of Glaukos from $127.00 to $136.00 and gave the company a “buy” rating in a report on Thursday. Finally, The Goldman Sachs Group reiterated a “buy” rating and issued a $138.00 price target on shares of Glaukos in a report on Friday, January 9th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $138.85.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the business. AustralianSuper Pty Ltd grew its stake in Glaukos by 10.8% in the third quarter. AustralianSuper Pty Ltd now owns 449,846 shares of the medical instruments supplier’s stock valued at $36,685,000 after purchasing an additional 43,750 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Glaukos by 4.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 670,083 shares of the medical instruments supplier’s stock valued at $54,645,000 after buying an additional 27,646 shares during the last quarter. SG Americas Securities LLC boosted its holdings in shares of Glaukos by 460.8% in the 4th quarter. SG Americas Securities LLC now owns 60,232 shares of the medical instruments supplier’s stock valued at $6,801,000 after buying an additional 49,492 shares during the last quarter. TD Asset Management Inc bought a new position in shares of Glaukos in the third quarter valued at $1,157,000. Finally, Allspring Global Investments Holdings LLC grew its stake in shares of Glaukos by 32.8% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 355,279 shares of the medical instruments supplier’s stock valued at $39,336,000 after buying an additional 87,781 shares in the last quarter. Institutional investors own 99.04% of the company’s stock.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.